Drug intelligence / Profile preview

phleum pratense allergenic extract

Development stage
Approved
Lead developer
ALK Abelló
Modality
Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Subcutaneous, Sublingual
01

Overview

Phleum pratense allergenic extract is a standardized allergen immunotherapy containing pollen extracts from Timothy grass (*Phleum pratense*). It is designed to induce immunological tolerance to grass pollen allergens in patients with allergic rhinitis or rhinoconjunctivitis. The extract contains major allergens (such as Phl p 1 and Phl p 5) that bind to IgE and are processed by antigen-presenting cells to be presented to T-cells. This exposure shifts the immune response from a Th2-dominated allergic response to a regulatory T-cell (Treg) response, characterized by the production of IL-10 and TGF-beta, and induces the production of allergen-specific IgG4 blocking antibodies that compete with IgE, thereby reducing allergic symptoms and inflammation upon subsequent exposure to grass pollen.

Brand names
ALK-depot SQAlutard SQ Phleum pratenseAlutard SQ TimotejGrastekGrazax
Other names
Phleum pratense extractPhleum pratense pollen extractTimothy grass allergenic extractTimothy grass pollen allergenic extractTimothy grass pollen extractstandardized Timothy grass pollen extract
02

Targets

FCER1 (Fc epsilon RI receptor)sIgG4 (Allergen-specific immunoglobulin G4)IgE (Immunoglobulin E)

Beyond the preview

Go deeper on phleum pratense allergenic extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on phleum pratense allergenic extract.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call